E2F4 and breast carcinoma: Extending beyond breast cancer, we preliminarily analyze E2F4 regulatory activity levels in bladder, colon, non-small cell lung, glioblastoma, acute myeloid leukemia, and Burkitt’s lymphoma cancer types, respectively, and find that they appear prognostic in colon, glioblastoma, and bladder cancer.